Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
暂无分享,去创建一个
[1] A. Zoubeidi,et al. Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells , 2020, Prostate cancer.
[2] R. Vrzal,et al. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells , 2020, Hormones and Cancer.
[3] M. Kanchwala,et al. Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence , 2020, bioRxiv.
[4] Sitao Wu,et al. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer , 2019, Science Translational Medicine.
[5] M. Kanchwala,et al. RELA is sufficient to mediate interleukin‐1 repression of androgen receptor expression and activity in an LNCaP disease progression model , 2019, The Prostate.
[6] A. D. De Marzo,et al. IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer , 2019, Molecular Cancer Research.
[7] F. Claessens,et al. The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models , 2018, Molecular Cancer Therapeutics.
[8] H. G. van der Poel,et al. Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐ and CXCL8‐mediated cancer cell migration , 2018, Molecular oncology.
[9] S. Barry,et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer , 2018, Nature.
[10] M. Kanchwala,et al. Identification of an IL‐1‐induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR− PCa cells , 2018, The Prostate.
[11] F. Hamdy,et al. Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1 , 2018, EMBO molecular medicine.
[12] G. Peng,et al. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer , 2017, Clinical Cancer Research.
[13] Jing Xu,et al. Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT , 2017, Cell Death & Disease.
[14] P. Nelson,et al. Expression of STAT3 in Prostate Cancer Metastases. , 2017, European urology.
[15] Xiaotao Li,et al. Reciprocal androgen receptor/interleukin‐6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis , 2017, The Journal of pathology.
[16] L. Reis,et al. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. , 2016, Urologic oncology.
[17] G. Kristiansen,et al. SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells , 2016, Molecular Cancer Research.
[18] S. Duensing,et al. IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2. , 2016, The American journal of pathology.
[19] Yezi Zhu,et al. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3‐AR axis inhibition , 2015, The Prostate.
[20] Hong-Chiang Chang,et al. Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals , 2015, Molecular oncology.
[21] Z. Jia,et al. Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer , 2015, British Journal of Cancer.
[22] M. Farach-Carson,et al. IL‐1β Induces p62/SQSTM1 and Represses Androgen Receptor Expression in Prostate Cancer Cells , 2014, Journal of cellular biochemistry.
[23] Hua Yu,et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. , 2014, Cancer research.
[24] Yezi Zhu,et al. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells , 2014, The Prostate.
[25] A. Zoubeidi,et al. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer , 2013, Molecular and Cellular Endocrinology.
[26] K. Kalland,et al. Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. , 2013, Cancer research.
[27] S. Yeh,et al. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling , 2013, Cell Death and Disease.
[28] O. Witte,et al. Interleukin-6 and Oncostatin-M Synergize with the PI3K/AKT Pathway to Promote Aggressive Prostate Malignancy in Mouse and Human Tissues , 2013, Molecular Cancer Research.
[29] W. Gerald,et al. Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer , 2012, Oncogene.
[30] P. Nelson,et al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR , 2011, Oncogene.
[31] H. Kung,et al. Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells , 2009, Clinical Cancer Research.
[32] Q. Tang,et al. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2 , 2009, Molecular Cancer Therapeutics.
[33] Haojie Huang,et al. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. , 2008, Cancer research.
[34] P. Johnston,et al. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. , 2008, Carcinogenesis.
[35] S. Araki,et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. , 2007, Cancer research.
[36] P. Johnston,et al. Interleukin-8 Signaling Promotes Translational Regulation of Cyclin D in Androgen-Independent Prostate Cancer Cells , 2007, Molecular Cancer Research.
[37] H. Klocker,et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.
[38] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.